This segment focuses on the research, development, and clinical trials of antisense oligonucleotide (ASO) medicines for severe neurological disorders. The primary focus is on Dravet syndrome, a rare and severe form of epilepsy, with STK-001 as the lead clinical candidate. Research and development activities include designing ASOs to precisely upregulate protein expression, preclinical studies, and Phase I/IIa clinical trials. The technology platform utilizes Targeted Augmentation of Nuclear Gene Output (TANGO) to address the underlying genetic causes of the disease. The patient impact is significant, as these therapies aim to provide disease-modifying treatments for a patient population with limited treatment options. Market positioning is based on being a pioneer in RNA-based therapies for genetic diseases. Future opportunities include expanding the pipeline to other neurological conditions and advancing clinical trials. Regulatory aspects involve working with the FDA and other regulatory bodies to gain approval for the therapies. Partnerships with companies like Biogen and Acadia Pharmaceuticals support the development and commercialization efforts.